Zobrazeno 1 - 10
of 83
pro vyhledávání: '"A K Golenkov"'
Autor:
A K Golenkov, I V Buravtsova, G A Dudina, T D Lutskaia, T A Mitina, E V Kataeva, A F Karamysheva, E S Kakpakova, Iu A Sablina, A A Stavrovskaia
Publikováno v:
Терапевтический архив, Vol 85, Iss 7, Pp 98-102 (2013)
AIM: To determine the significance of the angiogenic activity estimated from the gene expression of the vascular endothelial growth factors (VEGFs) VEGF-A, VEGF-C, and VEGF-D and their receptors VEGFR1, VEGFR1s, VEGFR2, and VEGFR3 in the mononuclear
Externí odkaz:
https://doaj.org/article/bdc6bdb6258e41b39621d4f6dc48fb05
Publikováno v:
Терапевтический архив, Vol 82, Iss 7, Pp 57-61 (2010)
Aim. To evaluate the effectiveness of bortezomib and bortezomib-containing treatment programs in the therapy of resistant and recurrent multiple myeloma (MM) within a large unicenter study in real clinical practice conditions. Subjects and methods. T
Externí odkaz:
https://doaj.org/article/a34873e0123a4b388baa16c96428a66b
Autor:
Anatoliy Konstantinovich Golenkov, Tat'yana Alekseevna Mitina, Ivetta Nikolaevna Kogarko, Nina Vasil'evna Lyubimova, Elena Fedorovna Klinushkina, Anatoliy Yur'evich Baryshnikov, A K Golenkov, T A Mitina, I N Kogarko, N V Lyubimova, E F Klikushkina, A Yu Baryshnikov
Publikováno v:
Терапевтический архив, Vol 81, Iss 7, Pp 37-41 (2009)
Aim. To ascertain individual sensitivity to veikeid in patients with resistant and recurrent multiple myeloma (MM) by determination of free light chains (FLC) of serum immunoglobulins. Material and methods. Forteen patients with MM stage III (Gcappa-
Externí odkaz:
https://doaj.org/article/8f9d4f0217fc4eca82cfca274c253e15
Autor:
T A Mitina, A K Golenkov
Publikováno v:
Терапевтический архив, Vol 80, Iss 7, Pp 48-50 (2008)
Aim. To assess efficacy of velcade monotherapy in patients with resistent and recurrent multiple myeloma (MM). Material and methods. Velcade was given to 29 patients (11 males and 18 females at the age 41-73 years) with resistant and recurrent MM of
Externí odkaz:
https://doaj.org/article/556b444dfff74293baee1aee566b7986
Autor:
A. A. Maschan, A. G. Rumyantsev, L. G. Kovaleva, B. V. Afanasiev, T. I. Pospelova, A. Yu. Zaritskiy, K. M. Abdulkadyrov, V. V. Ptushkin, N. V. Tsvetaeva, I. A. Lisukov, G. N. Salogub, A. K. Golenkov, N. V. Medvedeva, O. A. Rukavitsyn, V. L. Ivanova, I. V. Markova
Publikováno v:
Онкогематология, Vol 0, Iss 3, Pp 36-45 (2022)
New guidelines on diagnosis and treatment of a primary immune thrombocytopenia (ITP) in children and adults, on the basis of modern pathogenesis conceptions and considering possibilities of hematological practice in Russia are presented. Guidelines a
Externí odkaz:
https://doaj.org/article/6220b641931849d780f5e030ba86106b
Publikováno v:
Онкогематология, Vol 0, Iss 4, Pp 36-38 (2022)
Clinical efficiency of Dacogen (inhibitor of DNA hypermethylation) in 16 patients with MDS is presented. Bone marrow cytogenetic studies were performed in 6 patients; the detected chromosome aberrations included 5q deletion in 1 patient, X monosomy i
Externí odkaz:
https://doaj.org/article/97419dbb66be459c8485286dab601154
Autor:
K. A. Belousov, T. A. Mitina, Yu. Yu. Chuksina, A. K. Golenkov, E. V. Kataeva, E. V. Trifonova, Yu. B. Chernykh, L. L. Vysotskaya, S. G. Zakharov, E. F. Klinushkina, A. N. Mitin
Publikováno v:
Онкогематология, Vol 14, Iss 1, Pp 14-19 (2019)
Objective: to study the efficacy and safety of the antitumor RVP program (lenalidomide, bortezomib, prednisone) as a first-line therapy in patients with multiple myeloma (MM). Materials and methods. A prospective study involved 39 patients with MM (1
Externí odkaz:
https://doaj.org/article/9d44a6473ca940b5939c7131d1ff3f5b
Autor:
S. G. Zakharov, A. K. Golenkov, V. A. Misyurin, E. V. Kataeva, M. A. Baryshnikova, Yu. Yu. Chuksina, T. A. Mitina, E. V. Trifonova, L. L. Vysotskaya, Yu. B. Chernykh, E. F. Klinushkina, K. A. Belousov, Yu. P. Finashutina, A. V. Misyurin
Publikováno v:
Alʹmanah Kliničeskoj Mediciny, Vol 46, Iss 8, Pp 734-741 (2018)
Background: We have previously shown that the FAS, TNFR2, TRAIL, DR3, DR4/5 gene expression in patients with newly diagnosed chronic lymphoblastic leukemia (CLL) correlates with clinical manifestations of the disease: they are minimal in patients wit
Externí odkaz:
https://doaj.org/article/5700002fb2d745459e510326b80d8937
Autor:
Yu. B. Chernykh, A. K. Golenkov, S. S. Shushanov, T. A. Kravtsova, E. Yu. Rybalkina, A. F. Karamysheva, T. A. Mitina, E. V. Trifonova, E. V. Kataeva, L. L. Vysotskaya, A. A. Stavrovskaya
Publikováno v:
Alʹmanah Kliničeskoj Mediciny, Vol 44, Iss 5, Pp 624-630 (2017)
Background: Implementation of a proteasome inhibitor bortezomib into treatment of multiple myeloma has helped to improve survival of patients with this malignancy that is characterized by continuous relapsing course as a clinical manifestation of mul
Externí odkaz:
https://doaj.org/article/94caa4122f9e4aa3848952bfd3104a3a
Autor:
T. A. Мitina, A. K. Golenkov, A. Yu. Baryshnikov, A. V. Karaulov, E. V. Trifonova, Yu. B. Chernykh, E. V. Katayeva, T. D. Lutskaya, L. L. Vysotskaya, G. A. Dudina, S. G. Zacharov, A. M. Fomin, N. V. Lyubimova, I. N. Kogarko
Publikováno v:
Alʹmanah Kliničeskoj Mediciny, Vol 0, Iss 29, Pp 33-37 (2016)
Efficiency of the multiple myeloma treatment with chemotherapy including bortezomib was assessed based on determination of the level of immunoglobulin free light chains in blood serum. The method enables estimation of changes in kinetic parameters of
Externí odkaz:
https://doaj.org/article/05d3dfcce4404fb0a35c81461490811c